alpha-difluoromethylornithine ( dfmo ; eflornithine ) , an inhibitor of polyamine biosynthesis , was used to treat 14 patients with late stage gambiense sleeping sickness , 12 cases having been previously treated with and considered refractory to melarsoprol . alpha-difluoromethylornithine was administered intravenously at a dose of 400 mg/kg/day for 14 days followed by oral treatment , 300 mg/kg/day , for 21-28 days .
C0041228
sleeping
C0002260
alpha-difluoromethylornithine